Our Pricing

Understanding Semaglutide: Wegovy vs Ozempic in the UK

Published on: June 03, 2026

Many UK patients ask whether Wegovy and Ozempic the same UK medication, and the answer is both yes and no. Whilst both contain the active ingredient semaglutide, they're licensed for different purposes and formulated at different maximum doses. At Cured Pharmacy, our UK-registered clinical team helps patients understand which semaglutide option suits their needs, with Wegovy available from £79.00 following a free online consultation.

Are Wegovy and Ozempic the Same Medication?

Wegovy and Ozempic both contain semaglutide, a GLP-1 receptor agonist that mimics the action of the naturally occurring hormone glucagon-like peptide-1 [1]. This shared active ingredient means they work through identical mechanisms—slowing gastric emptying, reducing appetite, and improving glycaemic control. However, the MHRA has licensed these products for distinctly different indications in the UK.

Ozempic received UK marketing authorisation specifically for type 2 diabetes management, with approved doses ranging from 0.25mg to 2mg weekly [2]. Wegovy, conversely, is licensed exclusively for chronic weight management in adults with a BMI of 30 kg/m² or greater, or 27 kg/m² with weight-related comorbidities, escalating to a maximum maintenance dose of 2.4mg weekly [1]. This higher dose ceiling represents the key pharmaceutical difference between the two formulations.

Whilst the active pharmaceutical ingredient remains identical, prescribing Ozempic off-label for weight loss—a practice that became widespread during Wegovy supply shortages—raises regulatory and safety considerations. The MHRA and NHS England have issued guidance emphasising that clinicians should prescribe medications within their licensed indications wherever possible, particularly given that Wegovy's clinical trial programme specifically evaluated safety and efficacy at the higher 2.4mg dose for weight management [3].

Clinical Evidence: Wegovy and Ozempic Weight Loss Outcomes

The STEP clinical trial programme established Wegovy's efficacy specifically for weight management. In the landmark STEP 1 trial, participants receiving semaglutide 2.4mg weekly achieved an average body weight reduction of 14.9% over 68 weeks, compared to 2.4% with placebo [1]. This represented the most significant weight loss outcome for any pharmaceutical intervention available at the time of publication.

Ozempic's pivotal trials—the SUSTAIN programme—focused primarily on glycaemic control in type 2 diabetes, though weight loss emerged as a consistent secondary outcome. At the 1mg dose, participants experienced average weight reductions of 4.5kg to 6.5kg across various SUSTAIN studies [2]. The 2mg Ozempic dose, approved more recently, demonstrated weight loss approaching but not matching the 2.4mg Wegovy outcomes, averaging approximately 7kg reduction in SUSTAIN FORTE [4].

These differing trial designs reflect the products' distinct regulatory purposes. Wegovy trials enrolled participants based on BMI criteria alone, without requiring diabetes diagnosis, and used weight reduction as the primary endpoint. Ozempic trials recruited exclusively type 2 diabetes patients and measured HbA1c reduction as the primary outcome, with weight loss assessed secondarily. This fundamental difference in study populations and endpoints means direct comparison requires careful interpretation.

Real-World Effectiveness Considerations

Beyond controlled trial environments, real-world evidence suggests adherence and dose escalation significantly influence outcomes with both formulations. UK prescribers report that patients who successfully titrate to and maintain the maximum licensed dose—whether 2mg Ozempic for diabetes or 2.4mg Wegovy for weight management—achieve superior results compared to those remaining at lower maintenance doses. Gastrointestinal tolerability during dose escalation represents the most common barrier to reaching target doses, affecting approximately 40-50% of patients to varying degrees [1][2].

Can You Switch from Ozempic to Wegovy in the UK?

Switching between Ozempic and Wegovy is medically straightforward when clinically appropriate, as both deliver the same active molecule. UK prescribers typically recommend transitioning patients who were initially prescribed Ozempic off-label for weight loss to the appropriately licensed Wegovy formulation, particularly if supply constraints have resolved. The switch requires clinical assessment to ensure the patient meets Wegovy's licensing criteria—specifically the BMI thresholds and absence of contraindications.

The practical switching process depends on your current Ozempic dose. If you're established on Ozempic 1mg weekly, your prescriber will likely continue that dose as the next Wegovy injection, then follow Wegovy's standard escalation schedule toward 2.4mg if tolerated and clinically indicated. Patients on Ozempic 2mg may transition directly to Wegovy 2mg, with consideration for the final step to 2.4mg after at least four weeks. No washout period is necessary given the identical active ingredient.

From a regulatory perspective, switching from off-label Ozempic use to licensed Wegovy represents best practice prescribing. NHS England's 2023 guidance on GLP-1 receptor agonists for weight management explicitly states that where both products are available, Wegovy should be the preferred choice for patients seeking treatment primarily for obesity rather than diabetes management [3]. At Cured Pharmacy, our UK prescribers assess switching requests individually, ensuring continuity of care whilst optimising treatment within licensed parameters.

Insurance and Prescription Considerations

Patients switching from Ozempic to Wegovy should note that prescription charges and private pricing structures may differ between the products, despite containing the same active ingredient. This reflects the separate marketing authorisations and, in some cases, different reimbursement frameworks. Our clinical team provides transparent pricing information before any prescription is issued, ensuring you understand the financial implications of switching between formulations.

Wegovy vs Ozempic: Dosing Schedules and Administration

Both Wegovy and Ozempic utilise once-weekly subcutaneous injection via pre-filled, single-dose pens. The injection technique, storage requirements (refrigeration until first use), and administration sites (abdomen, thigh, or upper arm) remain identical across both products. This consistency means patients switching between formulations require no retraining on injection methodology.

The dose escalation schedules differ to accommodate each product's maximum licensed dose. Ozempic typically begins at 0.25mg weekly for four weeks (a dose intended to improve tolerability rather than provide therapeutic effect), increases to 0.5mg for at least four weeks, then to 1mg if additional glycaemic control is needed, with a possible further increase to 2mg [2]. Wegovy follows a more gradual five-step escalation: 0.25mg for four weeks, 0.5mg for four weeks, 1mg for four weeks, 1.7mg for four weeks, then the maintenance dose of 2.4mg [1].

The rationale for Wegovy's additional 1.7mg step relates to tolerability data from the STEP trials, which demonstrated that the extra escalation stage reduced discontinuation rates due to gastrointestinal adverse effects. UK prescribers may modify these standard schedules based on individual patient tolerance, occasionally extending time at intermediate doses or, in rare cases, maintaining patients at sub-maximal doses if the maximum dose proves intolerable despite producing adequate clinical response.

Cost Comparison: Wegovy and Ozempic Pricing in the UK

Pricing for semaglutide formulations varies significantly across UK pharmacies and depends heavily on dose strength and supply dynamics. At Cured Pharmacy, Wegovy is available from £79.00 following clinical assessment by our UK-registered prescribers—representing competitive UK pricing with transparent costs displayed before consultation. We guarantee the lowest prices in the UK market, with no hidden fees or surprise charges at checkout.

Ozempic pricing in the private market has historically been influenced by its dual use for both diabetes management and off-label weight loss, with demand fluctuations affecting availability. During periods when Wegovy faced supply constraints across UK pharmacies, Ozempic prescriptions for weight management increased substantially, occasionally creating access challenges for diabetes patients—the medication's primary licensed population. The MHRA and NHS England responded by issuing prescribing guidance to prioritise diabetes patients for Ozempic supplies.

When comparing costs between the two formulations, patients should consider the licensed maximum doses and treatment duration required to achieve clinical goals. Wegovy's 2.4mg maintenance dose represents the evidence-based target for optimal weight loss outcomes, whereas Ozempic's diabetes-focused licensing means the 2mg maximum may deliver less pronounced weight reduction. Our clinical team discusses cost-effectiveness alongside clinical suitability during your free online consultation, ensuring treatment decisions balance efficacy, safety, and affordability.

Understanding What's Included in Your Prescription Cost

At Cured Pharmacy, the price you see includes the medication, UK prescriber consultation, and discreet delivery to your address. There are no additional consultation fees or hidden prescription charges. Your treatment plan includes ongoing support from our UK-registered clinical team, with straightforward processes for prescription renewals, dose adjustments, or switching between formulations if clinically appropriate. All pricing is confirmed upfront before you complete your clinical assessment, ensuring complete transparency throughout your treatment journey.

Safety Profile: Side Effects and Contraindications

Given their shared active ingredient, Wegovy and Ozempic present virtually identical safety profiles and contraindication lists. The most frequently reported adverse effects are gastrointestinal: nausea affects approximately 44% of patients during dose escalation, with diarrhoea, constipation, and vomiting also common [1][2]. These effects typically diminish over 4-8 weeks as the body adapts to each new dose level, though a subset of patients experiences persistent symptoms requiring dose reduction or discontinuation.

Both medications carry important contraindications that UK prescribers must assess before prescribing. Personal or family history of medullary thyroid carcinoma represents an absolute contraindication, as does multiple endocrine neoplasia syndrome type 2, based on rodent study findings of thyroid C-cell tumours [1][2]. Patients with a history of pancreatitis require careful risk-benefit evaluation, as GLP-1 receptor agonists have been associated with acute pancreatitis in post-marketing surveillance, though causality remains debated in the medical literature.

Pregnancy and breastfeeding represent additional contraindications for both formulations. Semaglutide should be discontinued at least two months before planned conception due to its long half-life of approximately one week and limited human pregnancy data [1]. Women of childbearing potential should use effective contraception during treatment. UK prescribers at Cured Pharmacy conduct thorough medical history reviews during your online consultation to identify any contraindications or precautions specific to your circumstances, ensuring safe prescribing practices in line with MHRA guidance.

Monitoring Requirements During Treatment

Patients using either Wegovy or Ozempic should be monitored for signs of acute pancreatitis—persistent severe abdominal pain that may radiate to the back—and instructed to discontinue treatment immediately if this occurs. Regular review of weight loss progress, tolerability, and any emerging side effects should occur every 12-16 weeks, with treatment discontinued if insufficient response is achieved. Our clinical team at Cured Pharmacy provides ongoing support throughout your treatment journey, with straightforward access to UK prescribers if concerns arise between scheduled reviews.

Scientific References

1. Wilding, J. P. H., et al. (2021). Once-Weekly Semaglutide in Adults with Overweight or Obesity. New England Journal of Medicine, 384(11), 989–1002. https://doi.org/10.1056/NEJMoa2032183 [accessed 13 August 2026]
2. Sorli, C., et al. (2017). Efficacy and safety of once-weekly semaglutide monotherapy versus placebo in patients with type 2 diabetes (SUSTAIN 1): a double-blind, randomised, placebo-controlled, parallel-group, multinational, multicentre phase 3a trial. The Lancet Diabetes & Endocrinology, 5(4), 251–260. https://doi.org/10.1016/S2213-8587(17)30013-X [accessed 13 August 2026]
3. NHS England. (2023). Clinical Commissioning Policy: Semaglutide for weight management. NHS England. [accessed 13 August 2026]
4. Frías, J. P., et al. (2021). Efficacy and safety of once-weekly semaglutide 2.0 mg versus 1.0 mg in patients with type 2 diabetes (SUSTAIN FORTE): a double-blind, randomised, phase 3b trial. The Lancet Diabetes & Endocrinology, 9(9), 563–574. https://doi.org/10.1016/S2213-8587(21)00174-1 [accessed 13 August 2026]
5. NHS. (2026). Tirzepatide: a medicine to manage type 2 diabetes and treat obesity. https://www.nhs.uk/medicines/tirzepatide/ Accessed 13 August 2026.
6. NHS. (2026). Overweight and obesity in adults. https://www.nhs.uk/conditions/overweight-and-obesity/ Accessed 13 August 2026.
7. NHS England. (2026). Weight management injections. https://www.england.nhs.uk/ourwork/prevention/obesity/medicines-for-obesity/weight-management-injections/ Accessed 13 August 2026.

Information on this page is for educational purposes only and is not medical advice. All prescription treatments require clinical assessment by a UK-registered prescriber. Always consult a qualified healthcare professional before starting any new medication. Wegovy and Ozempic are prescription-only medicines containing semaglutide. Individual results may vary. Treatment outcomes described reflect average results from clinical trials and may not be representative of all patients. Side effects can occur—discuss risks and benefits with your prescriber.